Cagent Vascular and 3comma Medical Announce Strategic Partnership to Expand International Distribution of Serranator Product Family in EU and MENA Regions
Cagent Vascular, Inc., the exclusive developer of serration technology for vessel dilation in endovascular interventions, today announced its strategic partnership with 3comma Medical GmbH, a commercial services firm that specializes in bringing innovative medical device products to international markets. Under this collaboration, 3comma will serve as the exclusive international (OUS) distributor in EU and MENA regions for Cagent Vascular, leveraging its extensive network, industry expertise, and market insights to expedite the adoption of the Serranator® PTA Serration Balloon Product Family. This expansion builds upon the company’s commercial success and growth in the US market. The Serranator is a groundbreaking therapy for the treatment of peripheral artery disease (PAD) and chronic limb threatening ischemia (CLTI).
Cagent Vascular Announces Launch of New Product Serranator SL-PRO for CLTI and Pedal Disease
Cagent Vascular, Inc., the exclusive developer of serration technology for vessel dilation in endovascular interventions, today announced the launch of its newest product, Serranator SL-PRO™ PTA Serration Balloon Catheter.
Cagent Vascular appoints Chairman Brian Walsh to expanded role as Chief Executive Officer
Cagent Vascular announced today that Brian Walsh has been named Chief Executive Officer by the Cagent Vascular Board of Directors. He has served as Chairman of the Board since March 2018 and will continue in this capacity. Mr. Walsh will succeed Carol Burns as CEO.
Cagent Vascular announces initial RECOIL Study results: Serranator demonstrates 49% less recoil than POBA in BTK arteries
Cagent Vascular, the exclusive developer of serration technology for vessel dilatation in endovascular interventions, announced the results of its Below-the-Knee (BTK) RECOIL study. This Core Lab-Adjudicated Recoil analysis, the first of its kind, evaluated vessel recoil in lesions treated with Serranator® verses Plain Old Balloon Angioplasty (POBA). The study results demonstrated that lesions treated using Serration Angioplasty exhibited 49% less average recoil than POBA. Dr. Stefan Stahlhoff, MD (Arnsberg Clinic, Arnsberg, Germany) and Dr. Venita Chandra (Stanford University, Stanford, CA USA) led the RECOIL study as co-principal investigators.
Cagent Vascular announces superior lumen gain, greater volumetric blood flow using Serration Angioplasty: A sub-analysis of the PRELUDE BTK study
Cagent Vascular, the exclusive developer of Serration Angioplasty (Serranator®), announced the results of a comparative sub-analysis of the PRELUDE-Below-the-Knee (BTK) study versus Plain Old Balloon Angioplasty (POBA). The study was led by Dr. Marianne Brodmann (Radcliffe Cardiology, Graz, Austria). This sub-analysis compared their PRELUDE-BTK subset to a consecutive POBA group. The Serranator-treated lesions had an average final residual stenosis of 17.2 +/- (8.2%) versus 33.7 +/- (15.7%) in the POBA group. This represents a 49% average improvement in final residual stenosis. In Chronic Total Occlusions (CTO), there was a 62% improvement in final residual stenosis compared to the POBA group. The average balloon inflation pressure was 5 ATM in the Serranator group versus 9 ATM in the conventional balloon angioplasty group. Additionally, Serranator-treated arteries demonstrated 2.4 times greater calculated flow improvement versus POBA. These data, analyzed by the same independent core lab, were recently published in the Journal of Endovascular Therapy.
